| 영어 이름 | 연구 코드 | 연구 개발 단계 | 회사 | 적응증 | 임상 시험 |
|---|---|---|---|---|---|
| TAEST-1901 | TAEST-1901 | Phase 2 Clinical | Xiangxue Life Science Technology (Guangdong) Co Ltd | Liver Neoplasms; Neoplasms; Solid tumours; Stomach Neoplasms | 상세 |
| JWATM-203 | JWATM-203; JWATM203 | Phase 2 Clinical | Suzhou Yaomingjunuo Biotechnology Co Ltd | Carcinoma, Hepatocellular | 상세 |
| SynOV1.1 | SynOV1.1 | Phase 2 Clinical | Beijing Syngentech Co Ltd | Carcinoma, Hepatocellular; Solid tumours | 상세 |
| ET140203 | Phase 2 Clinical | Eureka Therapeutics Inc | Carcinoma, Hepatocellular; Hepatoblastoma; Liver Neoplasms | 상세 | |
| CPU-118 | CPU-118 | Phase 2 Clinical | China Pharmaceutical University, Nanjing Qinling Pharmaceutical Technology Co Ltd | Liver Neoplasms; Neoplasms; Solid tumours | 상세 |
| Alpha fetoprotein targeted T-cell therapy (Adaptimmune) | AFP TCR (ADP-A2AFP); ADP-A2AFP; AFP TCR; AFPc332T | Phase 1 Clinical | Adaptimmune Llc | Carcinoma, Hepatocellular | 상세 |